Novel Antischizophrenia Treatments, 2012 Handbook of Experimental Pharmacology Series, Vol. 213
Coordonnateurs : Geyer Mark A., Gross Gerhard
Preface.- Clinical instruments to evaluate and guide treatment in schizophrenia.- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders.- Nicotinic mechanisms in psychotic disorders.- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia.- Inhibitors of glycine transport as potential new treatments in schizophrenia.- The role of glutamate in schizophrenia.- Metabotropic glutamate receptors as targets for new treatments in schizophrenia.- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions.- Phosphodiesterase inhibitors as potential new treatments in schizophrenia.- Disease modifying approaches to schizophrenia.- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia.- Transgenic animals reflecting aspects of schizophrenia.- Behavioral animal models of pro-cognitive treatments for schizophrenia.
Provide up-to-date information on approaches to the discovery of treatments for cognitive deficits in schizophrenia
Provide information on promising new targets for therapeutics in the treatment of schizophrenia
Describe potential use of adjunctive co-treatments for use together with traditional antipsychotics
Includes supplementary material: sn.pub/extras
Date de parution : 11-2014
Ouvrage de 458 p.
15.5x23.5 cm
Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).
Prix indicatif 400,89 €
Ajouter au panierDate de parution : 10-2012
Ouvrage de 458 p.
15.5x23.5 cm
Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).
Prix indicatif 400,89 €
Ajouter au panierThèmes de Novel Antischizophrenia Treatments :
Mots-clés :
Cognition; Neurotransmitters; Psychopharmacology; Schizophrenia